Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Economic burden of migraine increases with the number of treatment failures

Publish date:: May 1, 2020

Key clinical point: The costs associated with migraine care increase with the number of treatment failures.

Major finding: Total per-patient medical cost per year for office visits was $35,392 among patients with three or more treatment failures.

Study details: A review of IBM MarketScan data for patients with a new diagnosis of migraine between Jan. 1, 2011, and June 30, 2015.

Disclosures: The study was supported by Novartis Pharma, one of the developers of erenumab. Dr. Newman has received compensation from Allergan, Alder, Amgen, Biohaven, Novartis, Teva, Supernus, and Theranica.

Citation:

Newman L et al. AAN 2020, Abstract S47.009.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Headache & Migraine

HIT-6 may help track meaningful change in chronic migraine,

Choroid plexuses may play a role in migraine,

Multiple traits more common in difficult-to-treat patients with migraine,

Marijuana for migraine? Some tentative evidence,

Low vitamin D levels in patients with migraine,